Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
publishDate:"[2022 TO 2022]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Severe+COVID-19+pneumonia%22&type=Subject&filter%5B%5D=publishDate%3A%22%5B2022+TO+2022%5D%22
/vufind/Search/Results?lookfor=%22Severe+COVID-19+pneumonia%22&type=Subject&filter%5B%5D=publishDate%3A%22%5B2022+TO+2022%5D%22
Search /vufind/Search2/Results?lookfor=%22Severe+COVID-19+pneumonia%22&type=Subject&filter%5B%5D=publishDate%3A%22%5B2022+TO+2022%5D%22
PubPharm (8)
1
ANTIcoagulation in Severe COVID-19 Patients : ANTIcoagulation in Severe COVID-19 Patients: a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial
enthalten in:
ClinicalTrials.gov
| 2022
Wird geladen...
2
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RECOMBINANT HUMAN PLASMA GELSOLIN (RHU-PGSN) ADDED TO STANDARD OF CARE FOR TREATMENT OF SUBJECTS WITH SEVERE COVID-19 PNEUMONIA : A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RECOMBINANT HUMAN PLASMA GELSOLIN (RHU-PGSN) ADDED TO STANDARD OF CARE FOR TREATMENT OF SUBJECTS WITH SEVERE COVID-19 PNEUMONIA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RECOMBINANT HUMAN PLASMA GELSOLIN (RHU-PGSN) ADDED TO STANDARD OF CARE FOR TREATMENT OF SUBJECTS WITH SEVERE COVID-19 PNEUMONIA : A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RECOMBINANT HUMAN PLASMA GELSOLIN (RHU-PGSN) ADDED TO STANDARD OF CARE FOR TREATMENT OF SUBJECTS WITH SEVERE COVID-19 PNEUMONIA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
Tocilizumab plus background therapy versus placebo plus background therapy in patients with severe COVID-19 pneumonia. : A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
Tocilizumab plus background therapy versus placebo plus background therapy in patients with severe COVID-19 pneumonia. : A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019(COVID-19)Pneumonia : A Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019(COVID-19)Pneumonia
enthalten in:
ClinicalTrials.gov
| 2022
Wird geladen...
7
The CO-ANNEXIN study; assessing the efficacy and safety of ANXV (recombinant Annexin A5) in moderate tosevere COVID-19. : A multiple dosing study to demonstrate the safety, tolerability, pharmacokinetics and efficacy potential ofintravenously administered ANXV (a recombinant human Annexin A5) in patients with confirmed moderate tosevere COVID-19; The CO-ANNEXIN Study. - The CO-ANNEXIN Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
The CO-ANNEXIN study; assessing the efficacy and safety of ANXV (recombinant Annexin A5) in moderate tosevere COVID-19. : A multiple dosing study to demonstrate the safety, tolerability, pharmacokinetics and efficacy potential ofintravenously administered ANXV (a recombinant human Annexin A5) in patients with confirmed moderate tosevere COVID-19; The CO-ANNEXIN Study. - The CO-ANNEXIN Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
[1]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Erscheinungsjahr: 2022-2022
Medienart
8
Aufsätze
8
E-Artikel
8
E-Ressourcen
Zeitschriftentitel
6
WHO International Clinical Trials Registry Plat...
2
ClinicalTrials.gov
Thema
8
610
8
Study Type: Interventional
6
Phase: Phase 2
4
Recruitment Status: Not yet recruiting
2
COVID-19
2
Medical Condition: Severe COVID-19 Pneumonia
2
Medical Condition: Severe COVID-19 pneumonia Me...
2
Medical Condition: moderate to severe COVID-19 ...
2
Medical Condition: severe COVID-19 pneumonia Me...
2
Phase: Phase 3
2
Recruitment Status: Authorised-recruitment may ...
2
Recruitment Status: Completed
1
Coronavirus Infections
1
Pneumonia
1
Virus Diseases
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2022-2022
Erscheinungsjahr(e)
Von:
Bis:
Sprache
8
Englisch
Haven't found what you're looking for?
Wird geladen...